ASCO 2020

Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas
Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas
MedCity News
Gilead Sciences
Yescarta
follicular lymphoma
marginal zone lymphoma
ASCO 2020
Kite Pharma
Flag link:
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
BioPharma Dive
Legend Biotech
IPOs
cancer
cell therapies
ASCO 2020
Flag link:
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
Flag link:
Asco 2020 movers – cell therapy companies dominate the risers
Asco 2020 movers – cell therapy companies dominate the risers
EP Vantage
ASCO 2020
cell therapy
Adaptimmune
Allogene
Iovance
Flag link:
Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential
Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential
MedCity News
Adaptimmune
ASCO 2020
cell therapy
sarcoma
ADP-A2M4
Flag link:
ASCO data for Amgen’s acute leukemia drug disappoint, but path forward remains, experts say
ASCO data for Amgen’s acute leukemia drug disappoint, but path forward remains, experts say
MedCity News
ASCO 2020
Amgen
AMG 330
acute myeloid leukemia
Flag link:
ASCO: Myovant details speedy effects of prostate cancer med relugolix
ASCO: Myovant details speedy effects of prostate cancer med relugolix
Fierce Biotech
Myovant
ASCO 2020
Relugolix
prostate cancer
clinical trials
Flag link:
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
Fierce Pharma
Merck
Eisai
liver cancer
ASCO 2020
Keytrua
Lenvima
clinical trials
Flag link:
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?
Fierce Pharma
AstraZeneca
ASCO 2020
clinical trials
tremelimumab
liver cancer
Imfinzi
Flag link:
Pfizer's Ibrance misses shot at big new market with early breast cancer failure
Pfizer's Ibrance misses shot at big new market with early breast cancer failure
Fierce Pharma
Pfizer
Ibrance
ASCO 2020
clinical trials
HER2-negative breast cancer
Flag link:
Gilead trumpets data with newly-bought magrolimab in blood cancers
Gilead trumpets data with newly-bought magrolimab in blood cancers
Pharmaforum
Gilead Sciences
ASCO 2020
Forty Seven
magrolimab
M&A
MDS
Flag link:
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
Pharmaforum
Daiichi Sankyo
AstraZeneca
Enhertu
stomach cancer
colorectal cancer
lung cancer
ASCO 2020
Flag link:
Ziopharm Phase I Trial Yields Positive Results for Treatment of rGBM
Ziopharm Phase I Trial Yields Positive Results for Treatment of rGBM
BioSpace
Ziopharm Oncology
rGBM
ASCO 2020
glioblastoma multiforme
clinical trials
Flag link:
Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial
Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial
BioSpace
Allogene
ASCO 2020
ALLO-501
clinical trials
refractory indolent non-Hodgkins lymphoma
Flag link:
AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead
AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead
Motley Fool
AstraZeneca
ASCO 2020
lung cancer
adjuvants
Tagrisso
Flag link:
ASCO 2020 virtual annual meeting – day 1 (live updates)
ASCO 2020 virtual annual meeting – day 1 (live updates)
Pharmaforum
ASCO 2020
virtual meetings
oncology
cancer
COVID-19
pandemic
Flag link:
Gilead’s newly bought immunotherapy drug scores at ASCO
Gilead’s newly bought immunotherapy drug scores at ASCO
MedCity News
Gilead Sciences
ASCO 2020
magrolimab
clinical trials
AML
MDS
Flag link:
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
Fierce Biotech
Allogene
ASCO 2020
CAR-T
ALLO-501
ALLO-647
lymphoma
Flag link:
AstraZeneca bid to expand lung cancer drug's use boosted by trial data
AstraZeneca bid to expand lung cancer drug's use boosted by trial data
BioPharma Dive
AstraZeneca
Tagrisso
lung cancer
clinical trials
ASCO 2020
Flag link:
ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients
ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients
Fierce Pharma
Merck
Keytruda
clinical trials
ASCO 2020
colorectal cancer
Flag link:

Pages